Urogen Pharma Ltd Corporate Analyst Meeting Transcript
Good morning, everybody. I'm Arie Belldegrun, and I want to welcome you to the UroGen Investor Day. I'm a urologist. I'm the Chairman of the company. And over 5 years ago, when I saw the technology, I really liked it. And let me try to explain you why and what at that time excited me about the technology. When I was a resident at the Brigham with Dr. Bob here, they taught us several principles that amazing since then didn't change. And that principles are very simple. Number one, in the kidney, ureter, bladder, as the bladder -- as the urine is flowing constantly, there is no difference between the upper tract and the lower urinary tract, it's a field defect. That's what we continued to teach -- I continue to teach at UCLA to our residents and fellows. It's a field defect. It's not what you see is that's the tumor. There is tumor antigens and there are oncogenes, and there are carcinogens in the urine that continue to flow, and therefore, everywhere you touch, the same issue is happening.
I'm a surgeon. We love surgery. And when you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |